{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"77"},{"groupId":"OG001","value":"73"},{"groupId":"OG002","value":"76"}],"units":"Participants"}],"description":"Common Terminology Criteria for Adverse Events (version 4) grades adverse event severity from 1=mild to 5=death. Summary data is provided in this outcome measure.; see Adverse Events Module for specific adverse event data.","groups":[{"description":"One Bupropion 150 mg XL capsule PO in a.m. daily for one week; one Bupropion 150 mg XL capsule and one placebo capsule PO in a.m. daily for 8 weeks; one placebo capsule daily PO in a.m. for one 1 week (titration off).","id":"OG000","title":"Bupropion 150 mg"},{"description":"One Bupropion 150 mg XL capsule PO in a.m. daily for one week; two Bupropion 150 mg XL capsules PO in a.m. daily for 8 weeks (300 mg target dose); one Bupropion 150 mg XL capsule PO in a.m. daily for 1 week (titration off)","id":"OG001","title":"Bupropion 300 mg"},{"description":"One placebo capsule PO in a.m. daily for 1 week; two placebo capsules PO in a.m. daily for 8 weeks; one placebo capsule PO in a.m. daily for 1 week (titration off)","id":"OG002","title":"Placebo"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Eligible with adverse event data and started study treatment.","reportingStatus":"POSTED","timeFrame":"Adverse events were evaluated 1,2,5,7, and 9 weeks from start of study treatment (within 21 days of randomization).","title":"Number of Participants With a Grade 3 or Higher Adverse Event Over the Course of the Study","type":"SECONDARY","unitOfMeasure":"Participants"}